A twelve 28-day cycles, multicenter, prospective, randomized, open, blinded endpoint, parallel group study comparing the effect on breast and cardiovascular metabolic markers of continuously combined 17[beta]-estradiol/dydrogesterone and tibolone in postmenopausal women.

Trial Profile

A twelve 28-day cycles, multicenter, prospective, randomized, open, blinded endpoint, parallel group study comparing the effect on breast and cardiovascular metabolic markers of continuously combined 17[beta]-estradiol/dydrogesterone and tibolone in postmenopausal women.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Apr 2010

At a glance

  • Drugs Estradiol/dydrogesterone; Tibolone
  • Indications Menopausal syndrome; Menopause
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Solvay Pharmaceuticals
  • Most Recent Events

    • 08 Apr 2009 Actual patient number amended from 136 to 135 as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Mar 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top